Home

DANE R SAGLIO

CIK 1263645 · Chief Financial Officer · last filed 2024-01-22

DANE R SAGLIO is a Chief Financial Officer who has filed 7 SEC Form 4 insider transactions across 3 companies since 2008. The most recent filing, for BFRGW, was dated Jan 22, 2024. Across all open-market trades the lifetime net is +$3.2K, making them a net buyer over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

3

Total Filings

7

Lifetime Open-Market Net

$3.2K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BFRGW Chief Financial Officer — $0.09 — $0 2 2024-01-22
New Generation Biofuels Holdings, Inc (NGBF) Delisted Chief Financial Officer — — — $0 1 2010-03-31
CASI Pharmaceuticals, Inc. (ENMD) Delisted Chief Financial Officer 664 — — $3.2K 3 2008-03-24

Recent Filings

7 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-01-22 BFRGW Grant (A) — $0 EDGAR
2023-03-22 BFRGW Grant (A) — $0 EDGAR
2011-02-14 — Grant (A) — $0
2010-03-31 New Generation Biofuels Holdings, Inc (NGBF) Delisted Grant (A) — $0 EDGAR
2008-03-24 CASI Pharmaceuticals, Inc. (ENMD) Delisted Buy (P) +3,000 $2.0K EDGAR
2008-03-20 CASI Pharmaceuticals, Inc. (ENMD) Delisted Buy (P) +2,000 $1.2K EDGAR
2008-01-03 CASI Pharmaceuticals, Inc. (ENMD) Delisted Grant (A) — $0 EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.